Tailoring Frontline Treatment Plans for Adults with Acute Myeloid Leukemia (AML) (Expired)
Faculty: Navel G. Daver, MD and Daniel Pollyea, MD, MS Grant Support: Agios and Astellas
Joint Providers: Postgraduate Institute for Medicine and Enquiring Minds, LLC
Access the Activity Online
Tailor treatment plans for 4 patients diagnosed with AML, each of whom may be experiencing new symptoms, comorbid conditions, recurrent disease, relapsed disease, or targetable mutations.
Margot
Margot is a 77-year-old woman with a history of atrial fibrillation, hypertension, and hypothyroidism who presented to her primary care provider 2 months ago with fatigue and dyspnea on exertion that had gradually progressed over the last 4 months.
Rafael
Rafael is a 62-year-old male who was diagnosed with AML 9 months previously, in the setting of a pneumonia and a petechial rash. Bone marrow biopsy showed a normal karyotype, 46, XY, and mutations in NPM1 and IDH1.
William
William is a 56-year-old construction worker who has been in a good state of health for most of his life. He has hyperlipidemia, for which he takes moderate-intensity atorvastatin. Over the last 2 to 4 weeks, he has noted worsening fatigue, dyspnea on exertion, and increased somnolence.
Jennifer
Jennifer is a 59-year-old with a medical history of hypertension treated with amlodipine, hyperlipidemia treated with atorvastatin, and coronary artery disease with 1 stent 5 years ago. She was diagnosed with AML: diploid cytogenetics, FLT3-internal tandem duplication (ITD) (allelic ratio 0.54), ASXL1, and TET2 mutations.